August 21, 2017 12:54 AM ET

Biotechnology

Company Overview of Raptor Pharmaceuticals Corp.

Company Overview

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. It also provides QUINSAIR, a formulation of the antibiotic drug levofloxacin for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients in Canada and Europe. The company’s clinical development pr...

7 Hamilton Landing

Suite 100

Novato, CA 94949

United States

Founded in 2005

158 Employees

Phone:

415-408-6200

Fax:

415-382-8002

Key Executives for Raptor Pharmaceuticals Corp.

Co-Founder and Chief Scientific Officer
Age: 53
Chief Financial Officer, Executive Vice President and Director
Age: 52
Chief Legal & Compliance Officer, Senior Vice President of Government Affairs and Secretary
Age: 42
Chief Commercial Officer
Age: 55
Chief Medical Officer
Age: 44
Compensation as of Fiscal Year 2017.

Raptor Pharmaceuticals Corp. Key Developments

Horizon Pharmaceutical LLC Files Form 15

Horizon Pharmaceutical LLC has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.

Raptor Pharmaceuticals Corp. Announces Cessation of Board of Directors; Announces Amendments to Certificate of Incorporation and the Bylaws

Raptor Pharmaceutical Corp. entered into an Agreement and Plan of Merger (the Merger Agreement), dated as of September 12, 2016, with Horizon Pharma plc (Parent), and Misneach Corporation and an indirect wholly owned subsidiary of Parent (Merger Sub). As of the Effective Time, each of Julie A. Smith, Gregg Lapointe, Raymond W. Anderson, Suzanne L. Bruhn Ph.D., Richard L. Franklin M.D., Ph.D., Georges Gemayel, Ph.D., Llew Keltner, M.D., Ph.D. and Christopher M. Starr, Ph.D., ceased serving as directors of Raptor, and the directors of Merger Sub as of the Effective Time, consisting of Timothy P. Walbert and Paul W. Hoelscher, became the sole directors of the Surviving Corporation. In connection with the consummation of the Merger, the certificate of incorporation of Raptor and the bylaws of Raptor were each amended and restated in their entirety.

Raptor Pharmaceutical Intends To File With SEC Certification And Notice Of Termination On Form 15, Requesting Deregistration Of Common Stock

Raptor Pharmaceutical Corp. entered into an Agreement and Plan of Merger (Merger Agreement), dated as of September 12, 2016, with Horizon Pharma plc (Parent) and Misneach Corporation (Merger Sub). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub commenced a tender offer to purchase all of the issued and outstanding shares (Shares) of Raptor’s common stock, par value $0.001 per share (Common Stock), for a purchase price of $9.00 per Share (Offer Price), payable to the holder thereof in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of September 26, 2016 (as amended or supplemented from time to time, the Offer to Purchase), and in the related Letter of Transmittal (as amended or supplemented from time to time, which, together with the Offer to Purchase, constitute the Offer). The Offer and withdrawal rights expired at the end of the day on October 24, 2016. Also on October 25, 2016, pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the Delaware General Corporation Law (DGCL), Merger Sub merged with and into Raptor (Merger), with Raptor continuing as the surviving corporation (Surviving Corporation). On October 25, 2016, Raptor Pharmaceutical notified The NASDAQ Global Market (NASDAQ) of the consummation of the Merger and requested that NASDAQ (i) suspend trading of the Common Stock before the opening of trading on October 25, 2016 and (ii) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act). Raptor intends to file with the SEC a Certification and Notice of Termination on Form 15, requesting the deregistration of the Common Stock under Section 12(g) of the Exchange Act and the suspension of Raptor’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 12, 2016
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Raptor Pharmaceuticals Corp., please visit www.raptorpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.